Abstract Details

Title Early, Sustained and Reversible Pharmacodynamic Effects of Daclizumab HYP in MS Support Mechanism of Action via Modulation of the IL-2 Pathway

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 149

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Lakshmi S. Amaravadi, PhD (Sr. Director, Translational Medicine) PRESENTER	No disclosure on file
Robert E. Hogan, MD (Washington Univ in St Louis/Neuro Dept)	Dr. Hogan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Hogan has received research support from Biogen Inc. The institution of Dr. Hogan has received research support from Engage Therapeutics. The institution of Dr. Hogan has received research support from Otsuka Pharmaceuticals. The institution of Dr. Hogan has received research support from Cerevel Therapeutics.
Devangi S. Mehta, PhD (Biogen)	No disclosure on file
Katherine A. Riester, MPH (Biogen)	No disclosure on file
James Sheridan, PhD (Abbott Labs)	No disclosure on file
Jacob S. Elkins, MD	No disclosure on file

��ɫ��